CVCVTE, n (%)

227 (65.6)

175 (64.6)

52 (69.3)

Anticoagulation,^{a} n (%)

199 (88)

153 (87)

46 (88)

No anticoagulation, n (%)

28 (12)

22 (13)

6 (12)

NonCVCVTE, n (%)

119 (34.4)

96 (35.4)

23 (30.7)

Anticoagulation,^{a} n (%)

110 (92)

88 (92)

22 (96)

No anticoagulation, n (%)

9 (8)

8 (8)

1 (4)

CVCVTE

Extremity/caval vein thrombosis/pulmonary embolism

89

34

Anticoagulation,^{a} n (%)

76 (85)

30 (88)

No anticoagulation, n (%)

13 (15)

4 (12)

Cardiac thrombosis

20

4

Anticoagulation,^{a} n (%)

18 (90)

4 (100)

No anticoagulation, n (%)

2 (10)

0

Renal vein thrombosis

1

0

Anticoagulation,^{a} n (%)

1 (100)

–

No anticoagulation, n (%)

0

–

Portal vein thrombosis

18

0

Anticoagulation,^{a} n (%)

14 (78)

–

No anticoagulation, n (%)

4 (22)

–

Jugular/subclavian vein thrombosis

47

14

Anticoagulation,^{a} n (%)

44 (94)

12 (86)

No anticoagulation, n (%)

3 (6)

2 (14)

NonCVCVTE

Cerebral venous sinus thrombosis

37

8

Anticoagulation,^{a} n (%)

34 (92)

8 (100)

No anticoagulation, n (%)

3 (8)

0

Extremity/caval vein thrombosis/pulmonary embolism

16

11

Anticoagulation,^{a} n (%)

14 (88)

11 (100)

No anticoagulation, n (%)

2 (13)

0

Cardiac thrombosis

12

0

Anticoagulation,^{a} n (%)

12 (100)

–

No anticoagulation, n (%)

0

–

Renal vein thrombosis^{b}

14

0

Anticoagulation,^{a} n (%)

12 (86)

–

No anticoagulation, n (%)

2 (14)

–

Portal vein thrombosis^{b}

14

1

Anticoagulation,^{a} n (%)

14 (100)

0

No anticoagulation, n (%)

0

1 (100)

Jugular/subclavian vein thrombosis

4

3

Anticoagulation,^{a} n (%)

3 (75)

3 (100)

No anticoagulation, n (%)

1 (25)

0
